BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K, Fukui I. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 2011;28:405-11. [PMID: 21365325 DOI: 10.1007/s10585-011-9379-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Beuselinck B, Pans S, Bielen J, De Wever L, Noppe N, Vanderschueren G, De Keyzer F, Baldewijns M, Lerut E, Laenen A, Verbiest A, Roussel E, Albersen M, Vandecaveye V. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors. Acta Oncol 2020;59:818-24. [PMID: 32297532 DOI: 10.1080/0284186X.2020.1750696] [Reference Citation Analysis]
2 Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J. Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer 2015;15:46. [PMID: 25872621 DOI: 10.1186/s12885-015-1050-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
3 McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014;66:502-9. [PMID: 24613250 DOI: 10.1016/j.eururo.2014.02.040] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
4 Grünwald V, Eberhardt B, Bex A, Flörcken A, Gauler T, Derlin T, Panzica M, Dürr HR, Grötz KA, Giles RH, von Falck C, Graser A, Muacevic A, Staehler M. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 2018;15:511-21. [PMID: 29904105 DOI: 10.1038/s41585-018-0034-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
5 Wong ECL, Kapoor A. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? Transl Oncol 2020;13:241-4. [PMID: 31869748 DOI: 10.1016/j.tranon.2019.10.009] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Onafowokan OO, Agrawal S, Middleton RG, Bartlett GE. Surgical management of renal cancer metastasis in the humerus: novel use of a trabecular metal spacer. BMJ Case Rep 2022;15:e244313. [PMID: 35140079 DOI: 10.1136/bcr-2021-244313] [Reference Citation Analysis]
7 Wood SL, Brown JE. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 2012;38:284-91. [PMID: 21802857 DOI: 10.1016/j.ctrv.2011.06.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
8 Zhai J, Liu N, Wang H, Huang G, Man L. Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases. Front Oncol 2021;11:659779. [PMID: 34221976 DOI: 10.3389/fonc.2021.659779] [Reference Citation Analysis]
9 Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther 2012;5:221-9. [PMID: 23055747 DOI: 10.2147/OTT.S30578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Yamasaki M, Yuasa T, Uehara S, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol 2016;21:1191-5. [PMID: 27402103 DOI: 10.1007/s10147-016-1019-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol 2013;18:877-83. [DOI: 10.1007/s10147-012-0472-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, Szczylik C, Sella A. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-Cancer Drugs 2013;24:431-40. [DOI: 10.1097/cad.0b013e328360335f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
13 Svensson E, Christiansen CF, Ulrichsen SP, Rørth MR, Sørensen HT. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open 2017;7:e016022. [PMID: 28893744 DOI: 10.1136/bmjopen-2017-016022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
14 Fan Z, Huang Z, Huang X. Bone Metastasis in Renal Cell Carcinoma Patients: Risk and Prognostic Factors and Nomograms. J Oncol 2021;2021:5575295. [PMID: 34054954 DOI: 10.1155/2021/5575295] [Reference Citation Analysis]
15 Casadei R, Drago G, Di Pressa F, Donati D. Humeral metastasis of renal cancer: Surgical options and review of literature.Orthop Traumatol Surg Res. 2018;104:533-538. [PMID: 29654934 DOI: 10.1016/j.otsr.2018.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Fischetti T, Di Pompo G, Baldini N, Avnet S, Graziani G. 3D Printing and Bioprinting to Model Bone Cancer: The Role of Materials and Nanoscale Cues in Directing Cell Behavior. Cancers (Basel) 2021;13:4065. [PMID: 34439218 DOI: 10.3390/cancers13164065] [Reference Citation Analysis]
17 Patel V, Patel S, Grossman S, Wali R, Burns M, Zebic L, Enting D, Henien M. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 4: miscellaneous cancers. Br Dent J 2022;232:213-8. [PMID: 35217738 DOI: 10.1038/s41415-022-3983-6] [Reference Citation Analysis]
18 Keizman D, Ish-Shalom M, Maimon N, Gottfried M. Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases? World J Urol 2014;32:39-45. [PMID: 23543006 DOI: 10.1007/s00345-013-1059-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Pu F, Zhang Z, Wang B, Liu J, Shao Z. En bloc resection and intercalary prosthesis implantation for the treatment of humeral diaphyseal bone metastases. Int Orthop 2021;45:281-8. [PMID: 33025082 DOI: 10.1007/s00264-020-04845-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Balagamwala EH, Angelov L, Koyfman SA, Suh JH, Reddy CA, Djemil T, Hunter GK, Xia P, Chao ST. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma: Clinical article. SPI 2012;17:556-64. [DOI: 10.3171/2012.8.spine12303] [Cited by in Crossref: 67] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]